{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:41:08Z","timestamp":1790775668830,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Medical Decision Modeling, Inc."},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,12,20]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>An important consideration in the treatment of patients with psoriatic arthritis (PsA) is whether the addition of methotrexate (MTX) to biologics has greater efficacy than biologic monotherapy with respect to efficacy outcomes in these patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To conduct a network meta-analysis (NMA) comparing biologics by treatment class with and without MTX for treatment of adults with active PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic literature review (SLR) identified randomised, double-blinded, controlled trials, and a Bayesian NMA compared biologics with and without MTX by treatment class (tumour necrosis factor inhibitors (TNFi), interleukin-23 inhibitors (IL-23i) and IL-17i). Efficacy outcomes included American College of Rheumatology 20%, 50% and 70% (ACR20, ACR50 and ACR70) improvement response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The SLR initially identified 31 studies, of which 17 met feasibility criteria for the NMA by containing the \u2018without MTX\u2019 subgroup. For ACR20 efficacy (the most robust assessment examined), all active treatments were significantly better than placebo. No statistically significant differences were demonstrated between biologic monotherapy (for all classes examined) and biologics in combination with MTX for ACR20\/50. IL-17i were comparable to IL-23i, and IL-17i were significantly better than TNFi for ACR20. Although limited by fewer trials, TNFi, IL-23i and IL-17i were not statistically different for ACR50\/70.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Concomitant use of MTX and biologics did not improve ACR efficacy outcomes versus biologic monotherapy. MTX does not appear to be necessary as a background therapy when biologics are used for the achievement of ACR20\/50 responses in patients with PsA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003423","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T23:00:21Z","timestamp":1706742021000},"page":"e003423","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct00317499","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Swedish Medical Center, Seattle, Washington, USA"},{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Reddy","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, New York University Grossman School of Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ross","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R","family":"Lisse","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Reis","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstin","family":"Griffing","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Sapin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Vadhariya","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E","family":"Furst","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"2025090313085183000_10.1.e003423.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.001"},{"key":"2025090313085183000_10.1.e003423.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025090313085183000_10.1.e003423.3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jaad.2014.05.010","article-title":"Comparative performance of Psoriatic arthritis screening tools in patients with psoriasis in European\/North American Dermatology clinics","volume":"71","author":"Mease","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2025090313085183000_10.1.e003423.4","first-page":"s225","article-title":"Psoriasis and Psoriatic arthritis treatment","volume":"22","author":"Menter","year":"2016","journal-title":"Am J Manag Care"},{"key":"2025090313085183000_10.1.e003423.5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ad.2015.10.005","article-title":"Methotrexate in moderate to severe psoriasis: review of the literature and expert recommendations","volume":"107","author":"Carrascosa","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"2025090313085183000_10.1.e003423.6","doi-asserted-by":"crossref","first-page":"105469","DOI":"10.1016\/j.jbspin.2022.105469","article-title":"The updated GRAPPA and EULAR recommendations for the management of Psoriatic arthritis: similarities and differences","volume":"90","author":"Coates","year":"2023","journal-title":"Joint Bone Spine"},{"key":"2025090313085183000_10.1.e003423.7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of Etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"The Lancet"},{"key":"2025090313085183000_10.1.e003423.8","doi-asserted-by":"publisher","DOI":"10.1186\/ar3147"},{"key":"2025090313085183000_10.1.e003423.9","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-05230-0"},{"key":"2025090313085183000_10.1.e003423.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204769"},{"key":"2025090313085183000_10.1.e003423.11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/1756-185X.13513","article-title":"Update of the APLAR recommendations for the treatment of rheumatoid arthritis","volume":"22","author":"Lau","year":"2019","journal-title":"Int J of Rheum Dis"},{"key":"2025090313085183000_10.1.e003423.12","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for Psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313085183000_10.1.e003423.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150614"},{"key":"2025090313085183000_10.1.e003423.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes001"},{"key":"2025090313085183000_10.1.e003423.15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40744-022-00436-x","article-title":"Experiences and treatment preferences in patients with Psoriatic arthritis: a cross-sectional study in the Arthritispower Registry","volume":"9","author":"Ogdie","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2025090313085183000_10.1.e003423.16","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14926","article-title":"Are Biologics combined with methotrexate better than Biologics monotherapy in psoriasis and Psoriatic arthritis: A meta-analysis of randomized controlled trials","volume":"34","author":"Xie","year":"2021","journal-title":"Dermatol Ther"},{"key":"2025090313085183000_10.1.e003423.17","unstructured":"National Institute for Health and Care Excellence . Developing NICE guidelines: the manual. Process and methods [PMG20], Available: https:\/\/www.nice.org.uk\/process\/pmg20\/chapter\/introduction"},{"key":"2025090313085183000_10.1.e003423.18","unstructured":"Higgins JPT , Thomas J , Chandler J , et al . Cochrane Handbook for systematic reviews of interventions version 6.3 (updated February 2022). 2022. Available: www.training.cochrane.org\/handbook"},{"key":"2025090313085183000_10.1.e003423.19","unstructured":"Chaimani A , Caldwell DM , Li T , et al . Chapter 11: undertaking network meta-analyses. In: Higgins JPT , Thomas J , Chandler J , et al ., eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.4. 2023. Available: www.training.cochrane.org\/handbook"},{"key":"2025090313085183000_10.1.e003423.20","unstructured":"Dias S , Welton NJ , Sutton AJ , et al . NICE DSU technical support document 2: A generalised linear Modelling framework for Pairwise and network meta-analysis of randomised controlled trials. 2011. Available: http:\/\/www.nicedsu.org.uk"},{"key":"2025090313085183000_10.1.e003423.21","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008929526011"},{"key":"2025090313085183000_10.1.e003423.22","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002195","article-title":"Sustained and improved Guselkumab response in patients with active Psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies","volume":"8","author":"Ritchlin","year":"2022","journal-title":"RMD Open"},{"key":"2025090313085183000_10.1.e003423.23","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/art.39685","article-title":"Brief report: Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active Psoriatic arthritis: INHIBITION OF JOINT STRUCTURAL DAMAGE WITH SECUKINUMAB","volume":"68","author":"van der Heijde","year":"2016","journal-title":"Arthritis & Rheumatology"},{"key":"2025090313085183000_10.1.e003423.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2025090313085183000_10.1.e003423.25","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/S2665-9913(20)30036-9","article-title":"Long-term efficacy and safety of Secukinumab in patients with Psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study","volume":"2","author":"McInnes","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"2025090313085183000_10.1.e003423.26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-Interleukin-17A Monoclonal antibody, in patients with Psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"The Lancet"},{"key":"2025090313085183000_10.1.e003423.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160275"},{"key":"2025090313085183000_10.1.e003423.28","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.23537","article-title":"Minimal disease activity among active Psoriatic arthritis patients treated with Secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Care & Research"},{"key":"2025090313085183000_10.1.e003423.29","doi-asserted-by":"crossref","unstructured":"Nash P , Mease PJ , McInnes IB , et al . Efficacy and safety of Secukinumab administration by Autoinjector in patients with Psoriatic arthritis: results from a randomized. Arthritis Res Ther 2018;20. doi:10.1186\/s13075-018-1551-x","DOI":"10.1186\/s13075-018-1551-x"},{"key":"2025090313085183000_10.1.e003423.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221019"},{"key":"2025090313085183000_10.1.e003423.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221048"},{"key":"2025090313085183000_10.1.e003423.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216500"},{"key":"2025090313085183000_10.1.e003423.33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214746"},{"key":"2025090313085183000_10.1.e003423.34","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/rheumatology\/keaa271","article-title":"Performance of composite measures used in a trial of Etanercept and methotrexate as monotherapy or in combination in Psoriatic arthritis","volume":"60","author":"Coates","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313085183000_10.1.e003423.35","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001484","article-title":"Patient-reported outcomes data in patients with Psoriatic arthritis from a randomised trial of Etanercept and methotrexate as monotherapy or in combination","volume":"7","author":"Strand","year":"2021","journal-title":"RMD Open"},{"key":"2025090313085183000_10.1.e003423.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"2025090313085183000_10.1.e003423.37","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057901"},{"key":"2025090313085183000_10.1.e003423.38","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151290"},{"key":"2025090313085183000_10.1.e003423.39","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus Adalimumab for treatment of active Psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3B trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"2025090313085183000_10.1.e003423.40","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bjd.20413","article-title":"Efficacy of Secukinumab and Adalimumab in patients with Psoriatic arthritis and concomitant Moderate\u2010To\u2010Severe plaque psoriasis: results from EXCEED, a randomized, Double\u2010Blind Head\u2010To\u2010Head monotherapy study","volume":"185","author":"Gottlieb","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025090313085183000_10.1.e003423.41","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"2025090313085183000_10.1.e003423.42","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"2025090313085183000_10.1.e003423.43","doi-asserted-by":"publisher","DOI":"10.1002\/art.22805"},{"key":"2025090313085183000_10.1.e003423.44","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.040196"},{"key":"2025090313085183000_10.1.e003423.45","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058339"},{"key":"2025090313085183000_10.1.e003423.46","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02388-5","article-title":"Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PSA: week 52 results from spirit-P1 and spirit-P2 studies","volume":"23","author":"Combe","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025090313085183000_10.1.e003423.47","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000181","article-title":"Comparative effectiveness of biologic monotherapy versus combination therapy for patients with Psoriatic arthritis: results from the Corrona Registry","volume":"1","author":"Mease","year":"2015","journal-title":"RMD Open"},{"key":"2025090313085183000_10.1.e003423.48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202347"},{"key":"2025090313085183000_10.1.e003423.49","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073544"},{"key":"2025090313085183000_10.1.e003423.50","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu415"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:08:59Z","timestamp":1756930139000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,31]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/rmdopen-2023-003423"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003423","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}